SMYD2 and chronic kidney disease: To elucidate the mechanism of action for SMYD2 in CKD, we established a CKD model in C57BL/6 mice via intraperitoneal injection of cisplatin and subsequently treated the cisplatin‐induced CKD mice with AZ505, a specific SMYD2 inhibitor (Figure 1B).